Media headlines about Immune Design (NASDAQ:IMDZ) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Immune Design earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.6488553365256 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Jefferies Group Weighs in on Immune Design Corp’s Q1 2018 Earnings (IMDZ) (americanbankingnews.com)
- Stocks Movement Analysis: Immune Design Corp. (NASDAQ:IMDZ), VeriFone Systems, Inc. (NYSE:PAY) – The Oracle Examiner (oracleexaminer.com)
- A quick recap Technical data on Immune Design Corp. (IMDZ) – Wall Street Morning (wallstreetmorning.com)
- Immune Design reports 4Q loss – Yahoo Finance (finance.yahoo.com)
- Immune Design Corp to Post FY2022 Earnings of ($0.67) Per Share, Jefferies Group Forecasts (IMDZ) (americanbankingnews.com)
A number of analysts have commented on the company. Zacks Investment Research lowered Immune Design from a “buy” rating to a “hold” rating in a report on Monday, January 8th. Jefferies Group reissued a “buy” rating and set a $8.00 price objective on shares of Immune Design in a report on Thursday, March 15th. Finally, Cowen reissued a “buy” rating on shares of Immune Design in a report on Monday, December 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $10.63.
Immune Design (NASDAQ:IMDZ) last released its earnings results on Wednesday, March 14th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.10. The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.81 million. Immune Design had a negative return on equity of 57.56% and a negative net margin of 720.81%. equities analysts predict that Immune Design will post -1.36 EPS for the current fiscal year.
In other news, CEO Carlos V. Paya sold 7,970 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $4.17, for a total value of $33,234.90. Following the completion of the transaction, the chief executive officer now directly owns 114,560 shares of the company’s stock, valued at $477,715.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Leo Guthart bought 20,000 shares of Immune Design stock in a transaction dated Monday, January 8th. The stock was acquired at an average cost of $3.90 per share, with a total value of $78,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 13,959 shares of company stock valued at $58,209. 20.70% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Immune Design (IMDZ) Given Daily News Impact Rating of 0.18” was first posted by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/2018/03/22/immune-design-imdz-getting-somewhat-positive-media-coverage-accern-reports/1925695.html.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.